Search Results 1031-1040 of 16437 for monoclonal antibody

1. Stem Cell Therapy Clinical Trials - Mayo Clinic Research

   Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after ...

2. A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU) - Mayo Clinic

   Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates ...

3. A Study Evaluating the Safety and Effectiveness of Anti-Influenza Intravenous Hyperimmune Immunoglobulin (IVIG) for Adults Hospitalized with Influenza - Mayo Clinic

   The purpose of this study is to test the safety and effectiveness of an antibody ... monoclonal gammopathy); Presence of any pre-existing illness that, in ...

4. Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52) - Mayo Clinic

   Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeks prior to study Day 1 or who has not recovered from adverse ...

5. A Multi-center, Open-label Extension, Safety Study of Mepolizumab in Subjects With Hypereosinophilic Syndrome (HES) From Study 200622 - Mayo Clinic

   Participation eligibility · Subjects with any history of hypersensitivity to any monoclonal antibody (including mepolizumab). · Subjects with current malignancy ...

6. A Study to Evaluate Effectiveness and Safety of MBG453 in Combination with Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS), or Chronic Myelomonocytic Leukemia-2 (CMML-2) - Mayo Clinic

   History of severe hypersensitivity reaction to any ingredients of the study treatments (azacitidine or MBG453) or their excipients, or to monoclonal antibodies.

7. A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Hematological Malignancies - Mayo Clinic

   Part 2 (Cohort Expansion): Subjects must have received adequate prior therapy including at a minimum including at a minimum anti-CD20 monoclonal antibody ...

8. Liposomal Cytarabine-Daunorubicin CPX-351, Fludarabine Phosphate, Cytarabine, and Filgrastim in Treating Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia - Mayo Clinic

   ... monoclonal antibodies), this period must be extended beyond the time during which acute adverse events are known to occur; Radiation therapy (RT): ≥ 2 weeks ...

9. A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma - Mayo Clinic

   ... monoclonal antibody, or Velcade® (bortezomib), cyclophosphamide, dexamethasone (VCd), and followed by a single or tandem autologous stem cell ...

10. A Study of Pembrolizumab (MK-3475) in Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma - Mayo Clinic

    Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not recovered from adverse events due to agents administered more than 4 ...